ORIGINAL_ARTICLE
The effect of salusin-β on expression of pro- and anti-inflammatory cytokines in human umbilical vein endothelial cells (HUVECs)
BACKGROUND: Atherosclerosis is one of the predominant causes of cardiovascular disease (CVD). Several studies indicated the significant pathophysiological role of salusin-β in atherosclerosis. Cytokines are involved in all stages of atherosclerosis. Therefore, we aimed to assess the effect of salusin-β on interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 18 (IL-18) (as inflammatory cytokines) and interleukin 1Ra (IL-1Ra) (as anti-inflammatory cytokines) levels in human umbilical vein endothelial cells (HUVECs).METHODS: The HUVECs were cultured in HUVEC completed medium and treated with different doses of salusin-β for 6 and 12 hours. For the investigation of nuclear factor ƙβ (NF-ƙβ) signaling pathway involvement, cells were treated in the presence or absence of Bay 11-7082 (as NF-ƙβ inhibitor). The mRNA expression and protein level of cytokines were measured by a real-time polymerase chain reaction (PCR) system and enzyme-linked immunosorbent assay (ELISA) method, respectively.RESULTS: Salusin-β increased mRNA expression and protein level of IL-6, IL-8 and IL-18. This protein decreased mRNA and protein level of IL-1Ra in HUVECs. NF-ƙβ signaling pathway was involved in the up-regulatory effect of salusin-β on mRNA expression of pro-inflammatory cytokines. The down-regulatory effect of salusin-β on IL-1Ra expression could not be influenced by Bay 11-7082 pre-treatment.CONCLUSION: It seems that salusin-β may participate in a cascade pathway in vascular inflammation. Our findings suggested that salusin-β has potential use as a therapeutic target for atherosclerosis.
https://arya.mui.ac.ir/article_10612_05050746bb8d011c9f4acc88d6d5d440.pdf
2018-01-27
1
10
10.22122/arya.v14i1.1602
Atherosclerosis
Cardiovascular Diseases
Cytokines
Endothelial Cells, Inflammation
Salusin-Beta
Maryam
Esfahani
esfahanimr21@yahoo.com
1
Isfahan Pharmaceutical Sciences Research Center AND Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoud
Saidijam
2
Professor, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
AUTHOR
Rezvan
Najafi
3
Assistant Professor, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
AUTHOR
Mohammad Taghi
Goodarzi
mtgoodarzi@yahoo.com
4
Professor, Research Center for Molecular Medicine AND Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
AUTHOR
Ahmad
Movahedian
movahedian@pharm.mui.ac.ir
5
Professor, Isfahan Pharmaceutical Sciences Research Center AND Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
World Health Organization. Cardiovascular disease: New initiative launched to tackle cardiovascular disease, the world's number one killer [Online]. [cited 2016]; Available from: URL: http://www.who.int/cardiovascular_diseases/global-hearts/Global_hearts_initiative/en.
1
Ramji DP, Davies TS. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev 2015; 26(6): 673-85.
2
Rezaee-Zavareh MS, Tohidi M, Sabouri A, Ramezani-Binabaj M, Sadeghi-Ghahrodi M, Einollahi B. Infectious and coronary artery disease. ARYA Atheroscler 2016; 12(1): 41-9.
3
Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006; 86(2): 515-81.
4
Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun 2008; 14(2): 63-87.
5
McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res 2011; 50(4): 331-47.
6
Loop T, Pahl HL. Activators and Target Genes of Rel/NF-êB Transcription Factors. In: Beyaert R, Editor. Nuclear Factor kB: Regulation and Role in Disease. Berlin, Germany: Springer Science & Business Media, 2003.
7
Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y. Salusins: Newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 2003; 9(9): 1166-72.
8
Sato K, Fujimoto K, Koyama T, Shichiri M. Release of salusin-beta from human monocytes/macrophages. Regul Pept 2010; 162(1-3): 68-72.
9
Watanabe T, Nishio K, Kanome T, Matsuyama TA, Koba S, Sakai T, et al. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008; 117(5): 638-48.
10
Koya T, Miyazaki T, Watanabe T, Shichiri M, Atsumi T, Kim-Kaneyama JR, et al. Salusin-beta accelerates inflammatory responses in vascular endothelial cells via NF-kappaB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am J Physiol Heart Circ Physiol 2012; 303(1): H96-105.
11
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
12
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-8.
13
Munoz C, Pascual-Salcedo D, Castellanos MC, Alfranca A, Aragones J, Vara A, et al. Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: Modulation of NF-kappa B and AP-1 transcription factors activity. Blood 1996; 88(9): 3482-90.
14
Nagashima M, Watanabe T, Shiraishi Y, Morita R, Terasaki M, Arita S, et al. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis 2010; 212(1): 70-7.
15
Zhou CH, Liu LL, Wu YQ, Song Z, Xing SH. Enhanced expression of salusin-beta contributes to progression of atherosclerosis in LDL receptor deficient mice. Can J Physiol Pharmacol 2012; 90(4): 463-71.
16
Apostolopoulos J, Davenport P, Tipping PG. Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol 1996; 16(8): 1007-12.
17
Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999; 19(2): 91-104.
18
Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res 2009; 84(3): 353-60.
19
DeForge LE, Fantone JC, Kenney JS, Remick DG. Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest 1992; 90(5): 2123-9.
20
Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170(6): 3369-76.
21
Cavusoglu E, Marmur JD, Yanamadala S, Chopra V, Hegde S, Nazli A, et al. Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome. Atherosclerosis 2015; 242(2): 589-94.
22
Sun HJ, Zhao MX, Ren XS, Liu TY, Chen Q, Li YH, et al. Salusin-beta promotes vascular smooth muscle cell migration and intimal hyperplasia after vascular injury via ROS/NFkappaB/MMP-9 pathway. Antioxid Redox Signal 2016; 24(18): 1045-57.
23
Ye SF, Wu YH, Hou ZQ, Zhang QQ. ROS and NF-kappaB are involved in upregulation of IL-8 in A549 cells exposed to multi-walled carbon nanotubes. Biochem Biophys Res Commun 2009; 379(2): 643-8.
24
Kim GY, Lee JW, Ryu HC, Wei JD, Seong CM, Kim JH. Proinflammatory cytokine IL-1beta stimulates IL-8 synthesis in mast cells via a leukotriene B4 receptor 2-linked pathway, contributing to angiogenesis. J Immunol 2010; 184(7): 3946-54.
25
Wang J, Sun C, Gerdes N, Liu C, Liao M, Liu J, et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med 2015; 21(7):
26
Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101(3): 711-21.
27
Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med 2002; 195(2): 245-57.
28
Morel JC, Park CC, Woods JM, Koch AE. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001; 276(40): 37069-75.
29
Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U, et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24(4): 750-5.
30
Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104(14): 1598-603.
31
Chandrasekar B, Valente AJ, Freeman GL, Mahimainathan L, Mummidi S. Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. Biochem Biophys Res Commun 2006; 339(3): 956-63.
32
Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006; 281(22): 15099-109.
33
Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89(7): E41-E45.
34
Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, et al. IL-12 synergizes with L-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol 2000; 12(2): 151-60.
35
Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115(1): 3-12.
36
Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010; 213(1): 21-9.
37
Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101(12): 1372-8.
38
Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: A comprehensive review of studies in mice. Cardiovasc Res 2008; 79(3): 360-76.
39
Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: Mechanisms, disease associations and management. Curr Pharm Des 2012; 18(11): 1478-93.
40
Zhou CH, Pan J, Huang H, Zhu Y, Zhang M, Liu L, et al. Salusin-beta, but not salusin-alpha, promotes human umbilical vein endothelial cell inflammation via the p38 MAPK/JNK-NF-kappaB pathway. PLoS One 2014; 9(9): e107555.
41
Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66(3): 583-93.
42
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160(2): 618-23.
43
Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20(11): 2394-400.
44
Isoda K, Ohsuzu F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J Atheroscler Thromb 2006; 13(1): 21-30.
45
Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008; 9: 8.
46
de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25(5): 904-14.
47
Venkatesan B, Valente AJ, Prabhu SD, Shanmugam P, Delafontaine P, Chandrasekar B. EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol 2010; 49(4): 655-63.
48
Chandrasekar B, Colston JT, de la Rosa SD, Rao PP, Freeman GL. TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochem Biophys Res Commun 2003; 303(4): 1152-8.
49
Suk K, Yeou KS, Kim H. Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: Involvement of NF-kB pathway in
50
the regulatory processes. Immunol Lett 2001; 77(2): 79-85.
51
ORIGINAL_ARTICLE
The Relationship between serum vitamin D levels and ankle-brachial index in patients with metabolic syndrome
BACKGROUND: Vitamin D deficiency is a prevalent condition in Iran and previous studies have shown that a low level of serum vitamin D is related to low ankle-brachial index (ABI). In the present study, the relationship of the serum level of vitamin D with ABI, as an index for atherosclerosis of peripheral arteries, was evaluated.METHODS: In this cross-sectional study, data on 91 patients with metabolic syndrome (Mets) from the Isfahan Cohort Study (ICS) were analyzed in order to evaluate the association between serum 25(OH) vitamin D level and ABI. The participants were divided into two groups; group A with desirable serum vitamin D level and group B with abnormal serum vitamin D level. ABI was measured and compared between these groups.RESULTS: A crude and adjusted model showed no association between vitamin D level and ABI in patients with MetS.CONCLUSION: It can be concluded that serum vitamin D level could not affect ABI in patients with MetS.
https://arya.mui.ac.ir/article_10613_f67d33c7b6120350f24a5e780f0456b0.pdf
2018-01-27
11
16
10.22122/arya.v14i1.1664
Vitamin D
Ankle Brachial Index
Metabolic Syndrome
Davoud
Kazemisaleh
m_sadeghi@crc.mui.ac.ir
1
Associate Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Keivan
Kiani
2
Resident, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoumeh
Sadeghi
sadeghimasoumeh@gmail.com
3
Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Hamidreza
Roohafza
hroohafza@gmail.com
4
Associate Professor, Psychosomatic Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Minoo
Dianatkhah
dianatkhah.m@gmail.com
5
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nizal
Sarrafzadegan
6
Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Sarrafzadegan N, Kelishadi R, Sadri G, Malekafzali H, Pourmoghaddas M, Heidari K, et al. Outcomes of a comprehensive healthy lifestyle program on cardiometabolic risk factors in a developing country: the Isfahan Healthy Heart Program. Arch Iran Med 2013; 16(1): 4-11.
1
Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004; 43(8): 1388-95.
2
Tomiyama H, Hirayama Y, Hashimoto H, Yambe M, Yamada J, Koji Y, et al. The effects of changes in the metabolic syndrome detection status on arterial stiffening: A prospective study. Hypertens Res 2006; 29(9): 673-8.
3
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(8): 731-3.
4
Roohafza H, Sadeghi M, Sarraf-Zadegan N, Baghaei A, Kelishadi R, Mahvash M, et al. Short communication: Relation between stress and other life style factors. Stress and Health 2007; 23: 23-9.
5
Khosravi-Boroujeni H, Sarrafzadegan N, Sadeghi M, Roohafza H, Ng SK, Pourmogaddas A, et al. Prevalence and trends of vitamin D deficiency among Iranian adults: A longitudinal study from 2001-2013. J Nutr Sci Vitaminol (Tokyo) 2017; 63(5): 284-90.
6
Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010; 33(6): 1379-81.
7
Makariou S, Liberopoulos EN, Elisaf M, Challa A. Novel roles of vitamin D in disease: What is new in 2011? Eur J Intern Med 2011; 22(4): 355-62.
8
Adragao T, Pires A, Branco P, Castro R, Oliveira A, Nogueira C, et al. Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant 2012; 27(1): 318-25.
9
Hosseini N, Talaei M, Dianatkhah M, Sadeghi M, Oveisgharan S, Sarrafzadegan N. Determinants of incident metabolic syndrome in a middle eastern population: Isfahan Cohort Study. Metab Syndr Relat Disord 2017; 15(7): 354-62.
10
Sarrafzadegan N, Gharipour M, Sadeghi M, Khosravi AR, Tavassoli AA. Metabolic syndrome in Iranian elderly. ARYA Atheroscler 2012; 7(4): 157-61.
11
Pasqualini L, Schillaci G, Pirro M, Vaudo G, Leli C, Colella R, et al. Prognostic value of low and high ankle-brachial index in hospitalized medical patients. Eur J Intern Med 2012; 23(3): 240-4.
12
Bouchi R, Babazono T, Takagi M, Yoshida N, Nyumura I, Toya K, et al. Non-linear association between ankle-brachial pressure index and prevalence of silent cerebral infarction in Japanese patients with type 2 diabetes. Atherosclerosis 2012; 222(2): 490-4.
13
Hsu PF, Chuang SY, Cheng HM, Tsai ST, Chou P, Chen CH. Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: A community-based study. Diabetes Res Clin Pract 2008; 79(3): 461-7.
14
Lin YC, Hsiao TJ, Chen PC. Persistent rotating shift-work exposure accelerates development of metabolic syndrome among middle-aged female employees: A five-year follow-up. Chronobiol Int 2009; 26(4): 740-55.
15
Sadeghi M, Talaei M, Oveisgharan S, Rabiei K, Dianatkhah M, Bahonar A, et al. The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort Study. Adv Biomed Res 2014; 3: 242.
16
Sadeghi M, Heidari R, Mostanfar B, Tavassoli A, Roghani F, Yazdekhasti S. The relation between ankle-brachial index (ABI) and coronary artery disease severity and risk factors: An angiographic study. ARYA Atheroscler 2011; 7(2): 68-73.
17
Wild SH, Byrne CD, Tzoulaki I, Lee AJ, Rumley A, Lowe GD, et al. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study. Atherosclerosis 2009; 203(2): 604-9.
18
Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: A prospective study. Circulation 2009; 120(12): 1041-7.
19
Saedisomeolia A, Taheri E, Djalali M, Moghadam AM, Qorbani M. Association between serum level of vitamin D and lipid profiles in type 2 diabetic patients in Iran. J Diabetes Metab Disord 2014; 13(1): 7.
20
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am J Hypertens 2007; 20(7): 713-9.
21
Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30(2 Pt 1): 150-6.
22
Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86(4): 1633-7.
23
Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995; 49(9): 640-6.
24
Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 2007; 71(2): 134-9.
25
Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28(5): 1228-30.
26
Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, Reeve J, et al. Reduced vitamin D in acute stroke. Stroke 2006; 37(1): 243-5.
27
Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41(1): 105-12.
28
Rajasree S, Rajpal K, Kartha CC, Sarma PS, Kutty VR, Iyer CS, et al. Serum 25-hydroxyvitamin D3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol 2001; 17(6): 567-71.
29
Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: A community-based study. Int J Epidemiol 1990; 19(3): 559-63.
30
Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
31
O'Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int 1996; 20(9): 621-4.
32
Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288(1): E125-E132.
33
Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007; 104(43): 16810-5.
34
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25 Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2): 229-38.
35
Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95(12): 787-96.
36
Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83(4): 754-9.
37
Kasuga H, Hosogane N, Matsuoka K, Mori I, Sakura Y, Shimakawa K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun 2002; 297(5): 1332-8.
38
ORIGINAL_ARTICLE
Prediction of the ischemic origin of functional mitral regurgitation in patients with systolic heart failure through posterior mitral leaflet angle
BACKGROUND: Differentiating ischemic from non-ischemic functional mitral regurgitation (FMR) in patients with cardiomyopathy is important in terms of the therapeutic decision-making and prognosis, but might be clinically challenging. In this study, the deformation of mitral valve (MV) indices in the prediction of the etiology of FMR was assessed using 2D transthoracic and tissue Doppler echocardiography.METHODS: This case-control study was conducted from April 2015 to January 2016 in Imam Reza Hospital in Mashhad, Iran. The participants consisted of 40 patients with ischemic cardiomyopathy (ICM) and 22 with non-ischemic dilated cardiomyopathy (DCM) who referred to the heart failure clinic. Transthoracic echocardiography was performed using the conventional 2D and tissue Doppler imaging (TDI). MV tenting area (TA), coaptation distance (CD), anterior and posterior mitral leaflet angles (AMLA and PMLA), and regional systolic myocardial velocity (Sm) were measured.RESULTS: There were no significant differences in echocardiographic indices between the two groups, besides Sm and PMLA which were significantly lower and higher, respectively, in ICM subjects in comparison with DCM patients (P = 0.002). PMLA ≥ 40 degrees and Sm ≤ 4 cm/second have a relatively high value for discriminating the ischemic from non-ischemic origin of functional MR in subjects with systolic heart failure (sensitivity: 80.0% and 70.0%, specificity: 73.0% and 77.3%; P = 0.001 and P < 0.001; respectively). Multivariable logistic regression identified PMLA and anterior Sm as major determinants for ischemic MR {Odds ratio (OR) [95% confidence interval (CI)] = 0.89 (0.82-0.96), P = 0.003, OR (95% CI) = 0.29 (0.14-0.60), P = 0.001, respectively}.CONCLUSION: The present study showed that PMLA and Sm had an independent significant association with the mechanism of FMR. These findings are suggestive of the predictive role of mitral deformation echocardiographic indices in the determination of the etiology of FMR in systolic heart failure.
https://arya.mui.ac.ir/article_10614_c9572d989343f1bf03b5a3b3e04694fe.pdf
2018-01-27
17
23
10.22122/arya.v14i1.1404
Ischemic
Cardiomyopathy
Systolic Heart Failure, Mitral Regurgitation
Transthoracic Echocardiography
Fereshteh
Ghaderi
1
Assistant Professor, Fellowship of Echocardiography, Atherosclerosis Prevention Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Farveh
Vakilian
vakilianf@mums.ac.ir
2
Associate Professor, Fellowship of Heart Failure, Atherosclerosis Prevention Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Pouya
Nezafati
pouya.nezafati@gmail.com
3
General Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan AND Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Omid Reza
Amini
aminio991@mums.ac.ir
4
Cardiologist, Atherosclerosis Prevention Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohammad Sobhan
Sheikh-Andalibi
5
Cardiovascular Research Center AND Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Bonow RO, Mann D, Zipes D, Libby P. Braunwald's heart disease: A textbook of cardiovascular medicine, single volume. 9th ed.
1
Philadelphia, PA: Saunders; 2015. p. 1479-80.
2
Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009; 373(9672): 1382-94.
3
Ng AC, Sindone AP, Wong HS, Freedman SB. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy. Int J Cardiol 2008; 129(2): 198-204.
4
Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: A quantitative clinical study. Circulation 2000; 102(12): 1400-6.
5
Brandt RR, Sperzel J, Pitschner HF, Hamm CW. Echocardiographic assessment of mitral regurgitation in patients with heart failure. Eur Heart J Suppl 2004; 6(suppl_D): D25.
6
Nagasaki M, Nishimura S, Ohtaki E, Kasegawa H, Matsumura T, Nagayama M, et al. The echocardiographic determinants of functional mitral regurgitation differ in ischemic and non-ischemic cardiomyopathy. Int J Cardiol 2006; 108(2): 171-6.
7
Sadeghpour A, Abtahi F, Kiavar M, Esmaeilzadeh M, Samiei N, Ojaghi SZ, et al. Echocardiographic evaluation of mitral geometry in functional mitral regurgitation. J Cardiothorac Surg 2008; 3: 54.
8
Donal E, De Place C, Kervio G, Bauer F, Gervais R, Leclercq C, et al. Mitral regurgitation in dilated cardiomyopathy: Value of both regional left ventricular contractility and dyssynchrony. Eur J Echocardiogr 2009; 10(1): 133-8.
9
Lesniak-Sobelga A, Wicher-Muniak E, Kostkiewicz M, Olszowska M, Musialek P, Klimeczek P, et al. Relationship between mitral leaflets angles, left ventricular geometry and mitral deformation indices in patients with ischemic mitral regurgitation: Imaging by echocardiography and cardiac magnetic resonance. Int J Cardiovasc Imaging 2012; 28(1): 59-67.
10
Konstantinou DM, Papadopoulou K, Giannakoulas G, Kamperidis V, Dalamanga EG, Damvopoulou E, et al. Determinants of functional mitral regurgitation severity in patients with ischemic cardiomyopathy versus nonischemic dilated cardiomyopathy. Echocardiography 2014; 31(1): 21-8.
11
Papadopoulou K, Giannakoulas G, Karvounis H, Dalamanga E, Karamitsos T, Parcharidou D, et al. Differences in echocardiographic characteristics of functional mitral regurgitation in ischaemic versus idiopathic dilated cardiomyopathy: A pilot study. Hellenic J Cardiol 2009; 50(1): 37-44.
12
Karaca O, Avci A, Guler GB, Alizade E, Guler E, Gecmen C, et al. Tenting area reflects disease severity and prognosis in patients with non-ischaemic dilated cardiomyopathy and functional mitral regurgitation. Eur J Heart Fail 2011; 13(3): 284-91.
13
Watanabe N, Ogasawara Y, Yamaura Y, Kawamoto T, Toyota E, Akasaka T, et al. Quantitation of mitral valve tenting in ischemic mitral regurgitation by transthoracic real-time three-dimensional echocardiography. J Am Coll Cardiol 2005; 45(5): 763-9.
14
Levine RA, Hagege AA, Judge DP, Padala M, Dal-Bianco JP, Aikawa E, et al. Mitral valve disease-morphology and mechanisms. Nat Rev Cardiol 2015; 12(12): 689-710.
15
Otsuji Y, Levine RA, Takeuchi M, Sakata R, Tei C. Mechanism of ischemic mitral regurgitation. J Cardiol 2008; 51(3): 145-56.
16
Gillam LD. Is it time to update the definition of functional mitral regurgitation?: Structural changes in the mitral leaflets with left ventricular dysfunction. Circulation 2008; 118(8): 797-9.
17
Gorman JH 3rd, Gorman RC, Plappert T, Jackson BM, Hiramatsu Y, St John-Sutton MG, et al. Infarct size and location determine development of mitral regurgitation in the sheep model. J Thorac Cardiovasc Surg 1998; 115(3): 615-22.
18
Magne J, Pibarot P, Dagenais F, Hachicha Z, Dumesnil JG, Senechal M. Preoperative posterior leaflet angle accurately predicts outcome after restrictive mitral valve annuloplasty for ischemic mitral regurgitation. Circulation 2007; 115(6): 782-91.
19
ORIGINAL_ARTICLE
Comparison of the effect of the Dietary Approaches to Stop Hypertension diet with usual dietary advice on expression of peroxisome proliferators-activated receptor gamma gene in women: A randomized controlled clinical trial
BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPAR-γ) which controls body weight, glucose homeostasis, and adipocyte differentiation is a valuable candidate gene for insulin resistance (IR). The present study aimed to compare the effects of the Dietary Approaches to Stop Hypertension (DASH) diet and usual dietary advice (UDA) on PPAR-γ gene expression in women at risk for cardiovascular disease (CVD).METHODS: This randomized controlled trial was performed on 44 women aged 20-50 years at risk for CVD (BMI > 25 kg/m2 and low physical activity). Participants were randomly assigned to the UDA (n = 22) or DASH (n = 22) diets for 12 weeks. The DASH diet was rich in fruits, vegetables, whole grains and low-fat dairy products and low in saturated fat, total fat, cholesterol, refined grains and sweets, with a total of 2400 mg/day sodium. The UDA diet was a regular diet with healthy dietary advice. Anthropometric indices and PPAR-γ gene expression were measured and compared between the two groups at the end of the study.RESULTS: After the intervention, body mass index (BMI) and waist circumference (WC) significantly decreased in the DASH group (P < 0.050) but the results showed no significant differences between the two groups. At the end of the trial, PPAR-γ gene expression was significantly different between the UDA and the DASH diet groups (P = 0.040) and this difference remained significant after adjustment for BMI, and physical activity (P = 0.030).CONCLUSION: The result of the study showed that the DASH diet significantly decreased the expression of PPAR-γ. This finding was unexpected and future studies on the current topic are therefore recommended.
https://arya.mui.ac.ir/article_10615_1ac301926bc0c32a27d56a27ec7a2f91.pdf
2018-01-27
24
31
10.22122/arya.v14i1.1565
Peroxisome Proliferator-Activated Receptor Gamma
DASH Diet
Gene Expression
Mohammad Hasan
Entezari
entezari@yahoo.com
1
Associate Professor, School of Nutrition and Food Sciences AND Food Security and Nutrition Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Rasol
Salehi
2
Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohammad
Kazemi
3
Assistant Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohsen
Janghorbani
janghorbani@yahoo.com
4
Professor, Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Marzieh
Kafeshani
marzikafeshani@hlth.mui.ac.ir
5
School of Nutrition and Food Sciences AND Food Security and Nutrition Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Mirhoseini M, Baradaran A, Rafieian-Kopaei M. Medicinal plants, diabetes mellitus and urgent needs. J Herbmed Pharmacol 2013; 2(2): 53-4.
1
Blumenthal JA, Babyak MA, Sherwood A, Craighead L, Lin PH, Johnson J, et al. Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids. Hypertension 2010; 55(5): 1199-205.
2
Kahn SE, Suvag S, Wright LA, Utzschneider KM. Interactions between genetic background, insulin resistance and beta-cell function. Diabetes Obes Metab 2012; 14(Suppl 3): 46-56.
3
Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem 2011; 57(2): 241-54.
4
Phillips CM. Nutrigenetics and metabolic disease: Current status and implications for personalised nutrition. Nutrients 2013; 5(1): 32-57.
5
Ghorbani A, Baradaran A. Magnesium and diabetes mellitus. J Renal Inj Prev 2012; 1(2): 46-7.
6
Hinderliter AL, Babyak MA, Sherwood A, Blumenthal JA. The DASH diet and insulin sensitivity. Curr Hypertens Rep 2011; 13(1): 67-73.
7
Niculescu MD. Are we ready for personalized dietary guidelines? J Hum Nutr Food Sci 2013; 1: 1013.
8
Garmaroudi G, Moradi A. Socio-Economic status in Iran: A study of measurement index. Payesh Health Monit 2010; 9(2): 137-44. [In Persian].
9
Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32(9 Suppl): S498-S504.
10
Sarkissian M. Food composition table of Iran. Tehran, Iran: Iran Institute of Nutrition Sciences and Food Technology; 1980. [In Persian].
11
Mahan LK, Escott-Stump S, Raymond JL, Krause MV. Krause's food & the nutrition care process. Philadelphia, PA: Elsevier Health Sciences; 2012.
12
Esmaeili A, Zaker SR. Differential expression of glycine receptor subunit messenger RNA in the rat following spinal cord injury. Spinal Cord 2011; 49(2): 280-4.
13
Adamo KB, Dent R, Langefeld CD, Cox M, Williams K, Carrick KM, et al. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity (Silver Spring) 2007; 15(5): 1068-75.
14
Ruiz-Narvaez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr 2007; 86(4): 1238-42.
15
Yongming P, Zhaowei C, Yichao M, Keyan Z, Liang C, Fangming C, et al. Involvement of peroxisome proliferator-activated receptors in cardiac and vascular remodeling in a novel minipig model of insulin resistance and atherosclerosis induced by consumption of a high-fat/cholesterol diet. Cardiovasc Diabetol 2015; 14: 6.
16
Baptista T, Sandia I, Fernandez E, Balzan L, Connell L, Uzcategui E, et al. Metabolic syndrome and related variables, insulin resistance, leptin levels, and PPAR-gamma2 and leptin gene polymorphisms in a pedigree of subjects with bipolar disorder. Rev Bras Psiquiatr 2015; 0: 0.
17
Soares FL, de Oliveira MR, Teixeira LG, Menezes Z, Pereira SS, Alves AC, et al. Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-alpha and PPAR-gamma expression. J Nutr Biochem 2013; 24(6): 1105-11.
18
Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25(6): 331-6.
19
Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123(6): 993-9.
20
Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26(5): 244-51.
21
Seymour EM, Lewis SK, Urcuyo-Llanes DE, Tanone II, Kirakosyan A, Kaufman PB, et al. Regular tart cherry intake alters abdominal adiposity, adipose gene transcription, and inflammation in obesity-prone rats fed a high fat diet. J Med Food 2009; 12(5): 935-42.
22
Liao W, Nguyen MT, Yoshizaki T, Favelyukis S, Patsouris D, Imamura T, et al. Suppression of PPAR-gamma attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007; 293(1): E219-E227.
23
Liu WX, Wang T, Zhou F, Wang Y, Xing JW, Zhang S, et al. Voluntary exercise prevents colonic inflammation in high-fat diet-induced obese mice by up-regulating PPAR-gamma activity. Biochem Biophys Res Commun 2015; 459(3): 475-80.
24
Long Y, Zhang XX, Chen T, Gao Y, Tian HM. Radix astragali improves dysregulated triglyceride metabolism and attenuates macrophage infiltration in adipose tissue in high-fat diet-induced obese male rats through activating mtorc1-PPAR gamma signaling pathway. PPAR Res 2014; 2014: 189085.
25
Liu Q, Wang CY, Liu Z, Ma XS, He YH, Chen SS, et al. Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-gamma/p38 MAPK signaling. Pharm Biol 2014; 52(9): 1085-93.
26
Lopez-Miranda J, Perez-Martinez P, Marin C,
27
Fuentes F, Delgado J, Perez-Jimenez F. Dietary fat, genes and insulin sensitivity. J Mol Med (Berl) 2007; 85(3): 213-26.
28
Hajjar T, Meng GY, Rajion MA, Vidyadaran S, Othman F, Farjam AS, et al. Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome proliferator activated receptors (PPARalpha and PPARgamma) gene expression in rats. BMC Neurosci 2012; 13: 109.
29
Abraham R, Ramakrishnan L, Parshad R, Seenu V, Prabhakaran D, Bahl V. Exploring the role of fatty acid on transcription factors regulating fatty acid metabolism with emphasis on trans fatty acid. Food Nutr Sci 2013; 4(9A): 33-8.
30
Bao L, Cai X, Dai X, Ding Y, Jiang Y, Li Y, et al. Grape seed proanthocyanidin extracts ameliorate podocyte injury by activating peroxisome proliferator-activated receptor-gamma coactivator 1alpha in low-dose streptozotocin-and high-carbohydrate/high-fat diet-induced diabetic rats. Food Funct 2014; 5(8): 1872-80.
31
Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47(2): 147-55.
32
Prakash J, Srivastava N, Awasthi S, Agarwal C, Natu S, Rajpal N, et al. Association of PPAR-gamma gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population. Am J Hum Biol 2012; 24(4): 454-9.
33
Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, et al. Comment: Studies of the pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: Homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87(8): 3989-92.
34
Medina-Gomez G, Virtue S, Lelliott C, Boiani R, Campbell M, Christodoulides C, et al. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 2005; 54(6): 1706-1.
35
ORIGINAL_ARTICLE
Epicardial fat thickness and severity of coronary heart disease in patients with diabetes mellitus type II
BACKGROUND: Clinical imaging studies have demonstrated a strong direct correlation between epicardial fat and abdominal visceral adiposity. There are several studies about positive correlation of epicardial fat and atherosclerotic coronary disease in general population. This study aimed to evaluate the association of epicardial fat thickness with atherosclerotic coronary disease in patients with diabetes mellitus type II.METHODS: This cross-sectional observational study involved 80 patients with diabetes mellitus type II. The patients were chosen using simple sampling method from patients with diabetes mellitus who were referred for angiography because of suspected coronary artery disease. The severity of coronary atherosclerotic lesions was evaluated using modified Gensini scoring system. Epicardial fat thickness was measured by transthoracic echocardiography within 90 days after coronary angiography. Multiple linear regression method was used to evaluate the association between mean epicardial fat thickness and Gensini score.RESULTS: After adjustment for the effects of body mass index (BMI), age, angina, and sex, there was a significant association between Gensini score and epicardial fat thickness (β = 0.825; P < 0.001). Patients with higher blood pressure and higher body mass index also had a higher Gensini score (P < 0.010)CONCLUSION: In patients with diabetes mellitus type II, there is a positive association between epicardial fat thickness and severity of coronary artery disease. So, by echocardiography evaluation of epicardial fat thickness, we could have an estimation of the severity of coronary arteries diseases before using more invasive techniques.
https://arya.mui.ac.ir/article_10616_fb1bda40c82ad6d9e4869cd63d3f91d7.pdf
2018-01-27
32
37
10.22122/arya.v14i1.1552
Epicardial Fat Thickness
Coronary Stenos
Diabetes Mellitus
Ali
Nasri
1
Assistant Professor, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Jamshid
Najafian
jamshid_najafian@yahoo.com
2
Associate Professor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Seied Majid
Drakhshandeh
3
Cardiologist, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute AND Department of Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Faezeh
Madjlesi
4
General Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: The Rotterdam study. Int J Obes Relat Metab Disord 2001; 25(11): 1730-5.
1
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study.
2
Circulation 1983; 67(5): 968-77.
3
Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322(13): 882-9.
4
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149(7): 1514-20.
5
Washio M, Hayashi R. Past history of obesity (overweight by WHO criteria) is associated with an increased risk of nonfatal acute myocardial infarction: A case-control study in Japan. Circ J 2004; 68(1): 41-6.
6
Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR, Gustafson AB, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989; 110(11): 867-72.
7
Rabkin SW. Epicardial fat: Properties, function and relationship to obesity. Obes Rev 2007; 8(3): 253-61.
8
Sengul C, Ozveren O. Epicardial adipose tissue: A review of physiology, pathophysiology, and clinical applications. Anadolu Kardiyol Derg 2013; 13(3): 261-5.
9
Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007; 13(21): 2180-4.
10
Maurovich-Horvat P, Kallianos K, Engel LC, Szymonifka J, Schlett CL, Koenig W, et al. Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers. Obesity (Silver Spring) 2015; 23(6): 1178-84.
11
Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging 2010; 3(4): 352-60.
12
Karastergiou K, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol 2010; 30(7): 1340-6.
13
Iacobellis G, Willens HJ. Echocardiographic epicardial fat: A review of research and clinical applications. J Am Soc Echocardiogr 2009; 22(12): 1311-9.
14
Jameson J, Fauci A, Kasper D, Hauser S, Loscalzo J. Harrison's principles of internal medicine. New York, NY: McGraw Hill Professional, 2011.
15
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44(3): 720-32.
16
Lilly LS, Braunwald E. Braunwald's heart disease: A textbook of cardiovascular medicine. Philadelphia, PA: Elsevier Health Sciences; 2012. p. 396-9.
17
Gensini GG. Coronary arteriography. Austin, TX: Futura Pub. Co; 1975.
18
Bhuiyan GR, Roy GC, Siddique MA, Rahman M, Ahmed K, Nahar F. Relationship between echocardiographic epicardial adipose tissue (EAT) thickness and angiographically detected coronary artery disease. Mymensingh Med J 2017; 26(3): 498-504.
19
Sato F, Maeda N, Yamada T, Namazui H, Fukuda S, Natsukawa T, et al. Association of epicardial, visceral, and subcutaneous fat with cardiometabolic diseases. Circ J 2018; 82(2): 502-8.
20
Meenakshi K, Rajendran M, Srikumar S, Chidambaram S. Epicardial fat thickness: A surrogate marker of coronary artery disease-Assessment by echocardiography. Indian Heart J 2016; 68(3): 336-41.
21
Nakazato R, Dey D, Cheng VY, Gransar H, Slomka PJ, Hayes SW, et al. Epicardial fat volume and concurrent presence of both myocardial ischemia and obstructive coronary artery disease. Atherosclerosis 2012; 221(2): 422-6.
22
Uygur B, Celik O, Ozturk D, Erturk M, Otcu H, Ustabasioglu FE, et al. The relationship between location-specific epicardial adipose tissue volume and coronary atherosclerotic plaque burden in type 2 diabetic patients. Kardiol Pol 2017; 75(3): 204-12.
23
Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J 1990; 268(2): 287-94.
24
Murai T, Takebe N, Nagasawa K, Todate Y, Nakagawa R, Nakano R, et al. Association of epicardial adipose tissue with serum level of cystatin C in type 2 diabetes. PLoS One 2017; 12(9): e0184723.
25
Moreno-Santos I, Perez-Belmonte LM, Macias-Gonzalez M, Mataro MJ, Castellano D, Lopez-Garrido M, et al. Type 2 diabetes is associated with decreased PGC1alpha expression in epicardial adipose tissue of patients with coronary artery disease. J Transl Med 2016; 14(1): 243.
26
Ng AC, Goo SY, Roche N, van der Geest RJ, Wang WY. Epicardial Adipose Tissue Volume and Left Ventricular Myocardial Function Using 3-Dimensional Speckle Tracking Echocardiography. Can J Cardiol 2016; 32(12): 1485-92.
27
Gauss S, Klinghammer L, Achenbach S, Garlichs CD. Association of Systemic Inflammation Markers with the Presence and Progression of Coronary Artery Calcification and Epicardial Fat Volume. J Am Coll Cardiol 2013; 61(10, Suppl): E1152.
28
Hwang IC, Park HE, Choi SY. Epicardial Adipose
29
Tissue Contributes to the Development of Non-Calcified Coronary Plaque: A 5-Year Computed Tomography Follow-up Study. J Atheroscler Thromb 2017; 24(3): 262-74.
30
Rajani R, Dey D, Nakazato R, Wong N. Differential effects of epicardial fat volume on coronary, Aortic valve and aortic calcification. J Am Coll Cardiol 2011; 57(14): E878 •.
31
Ito T, Nasu K, Terashima M, Ehara M, Kinoshita Y, Ito T, et al. The impact of epicardial fat volume on coronary plaque vulnerability: Insight from optical coherence tomography analysis. Eur Heart J Cardiovasc Imaging 2012; 13(5): 408-15.
32
Ito T, Fujita H, Ichihashi T, Ohte N. Impact of epicardial adipose tissue volume quantified by non-contrast electrocardiogram-gated computed tomography on ergonovine-induced epicardial coronary artery spasm. Int J Cardiol 2016; 221: 877-80.
33
ORIGINAL_ARTICLE
Unusual management of parturient patient with severe bicuspid aortic valve stenosis and congestive heart failure
BACKGROUND: Critical aortic stenosis (AS) is an unusual cardiac pathology in pregnancy, but has significant impact on the fetal and maternal outcomes of pregnancy. Pregnant patients with aortic stenosis and heart failure represent a major challenge for the heart team and anesthesiologist who should balance the risks and benefits of different treatment strategies and their effects on the mother and fetus.CASE REPORT: We present a 26-year-old parturient who underwent cesarean section at 30 weeks of gestation under general anesthesia in the presence of cardiac surgical team followed by deferred aortic valve replacement after two weeks.CONCLUSION: This report describes the importance of multidisciplinary preoperative evaluation, and careful surgical and anesthetic planning to avoid the deterioration of perioperative cardiac condition in such patients.
https://arya.mui.ac.ir/article_10617_5adcd088040409d3e359547218fb0a94.pdf
2018-01-27
38
40
10.22122/arya.v14i1.1607
Pregnancy
Aortic stenosis (AS)
Bicuspid aortic valve (BAV)
aortic valve replacement (AVR)
congestive heart failure (CHF)
Mahdi
Kahrom
kahrommh@mums.ac.ir
1
Department of Cardiovascular Surgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Mostafa
Ahmadi
ahmadim@mums.ac.ir
2
Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Behrooz
Mottahedi
mottahedib@mums.ac.ir
3
Department of Cardiovascular Surgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Masoomeh
Tabari
4
Department of Anesthesiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Atieh
Vatanchi
5
Department of Gynecology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Naser
Paravi
6
Department of Anesthesiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hamid
Ghaderi
7
Department of Cardiovascular Surgery, Chamran Heart Center, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Datt V, Tempe DK, Virmani S, Datta D, Garg M, Banerjee A, et al. Anesthetic management for emergency cesarean section and aortic valve replacement in a parturient with severe bicuspid aortic valve stenosis and congestive heart failure. Ann Card Anaesth 2010; 13(1): 64-8.
1
Banning AP, Pearson JF, Hall RJ. Role of balloon dilatation of the aortic valve in pregnant patients with severe aortic stenosis. Br Heart J 1993; 70(6): 544-5.
2
Podder S, Kumar A, Mahajan S, Saha PK. Initial non-opioid based anesthesia in a parturient having severe aortic stenosis undergoing cesarean section with aortic valve replacement. Ann Card Anaesth 2015; 18(1): 98-100.
3
Yap SC, Drenthen W, Pieper PG, Moons P, Mulder BJ, Mostert B, et al. Risk of complications during pregnancy in women with congenital aortic
4
stenosis. Int J Cardiol 2008; 126(2): 240-6.
5
Ben-Ami M, Battino S, Rosenfeld T, Marin G, Shalev E. Aortic valve replacement during pregnancy. A case report and review of the literature. Acta Obstet Gynecol Scand 1990; 69(7-8): 651-3.
6
Yuan SM. Bicuspid aortic valve in pregnancy. Taiwan J Obstet Gynecol 2014; 53(4): 476-80.
7
Yentis SM, Dob DP. Caesarean section in the presence of aortic stenosis. Anaesthesia 1998; 53(6): 606-7.
8
Strickland RA, Oliver WC Jr, Chantigian RC, Ney JA, Danielson GK. Anesthesia, cardiopulmonary bypass, and the pregnant patient. Mayo Clin Proc 1991; 66(4): 411-29.
9
Fanning N, Balki M, Sermer M, Colman J, Carvalho JC. Noninvasive cardiac output monitoring during general anesthesia for Cesarean delivery in a patient with severe aortic stenosis. Can J Anaesth 2011; 58(9): 837-41.
10
ORIGINAL_ARTICLE
A rare case of spontaneous and simultaneous multivessel coronary artery spasm leading to multisite myocardial infarction and ventricular fibrillation
BACKGROUND: Coronary artery spasm (CAS) can result in life-threatening arrhythmia and sudden cardiac death. Although this disorder has been known for a long time, little is known about it, and its mechanisms have been not identified yet.CASE REPORT: We describe a 52-year-old woman with no significant cardiovascular risk factors who experienced several episodes of spontaneous and coincident multivessel coronary artery spasm, which led to myocardial infarction as well as malignant arrhythmias. Coronary angiography revealed severe migratory narrowing in the left anterior descending artery and right coronary artery.CONCLUSION: Simultaneous multivessel coronary artery spasm develop multisite myocardial infarction (MI), and malignant arrhythmias could occur even in the absence of significant stenosis and triggering factors, which would lead to an increased risk of life-threatening cardiac events.
https://arya.mui.ac.ir/article_10618_6d5d6d2428eb6ef596569cc775870b76.pdf
2018-01-27
41
43
10.22122/arya.v14i1.1683
Variant Angina
Coronary Artery Spasm
Acute Myocardial Infraction
Coronary Angiography
Leili
Iranirad
1
Assistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Mohammad Saleh
Sadeghi
salehsadeghi87@gmail.com
2
Researcher AND General Practitioner, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
LEAD_AUTHOR
MacAlpin RN. Some observations on and controversies about coronary arterial spasm. Int J Cardiol 2015; 181: 389-98.
1
Kusama Y, Kodani E, Nakagomi A, Otsuka T, Atarashi H, Kishida H, et al. Variant angina and coronary artery spasm: The clinical spectrum, pathophysiology, and management. J Nippon Med Sch 2011; 78(1): 4-12.
2
de Luna AB, Cygankiewicz I, Baranchuk A, Fiol M, Birnbaum Y, Nikus K, et al. Prinzmetal angina: ECG changes and clinical considerations: A consensus paper. Ann Noninvasive Electrocardiol 2014; 19(5): 442-53.
3
Hung MJ, Hu P, Hung MY. Coronary artery spasm: Review and update. Int J Med Sci 2014; 11(11): 1161-71.
4
Falsoleiman H, Bayani B, Dehghani M, Moohebati M, Rohani A. Global coronary arteries spasm in a young patient. ARYA Atheroscler 2013; 9(4): 260-2.
5
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61(4): e78-140.
6
Chuang YT, Ueng KC. Spontaneous and simultaneous multivessel coronary spasm causing multisite myocardial infarction, cardiogenic shock, atrioventricular block, and ventricular fibrillation. Circ J 2009; 73(10): 1961-4.
7
Hendriks ML, Allaart CP, Bronzwaer JG, Res JJ, de Cock CC. Recurrent ventricular fibrillation caused by coronary artery spasm leading to implantable cardioverter defibrillator implantation. Europace 2008; 10(12): 1456-7.
8
Hovasse T, Jariwala P, Lefevre T. Spontaneous coronary artery spasm during-įcoronary angiography: An uncommon manifestation of variant angina. Journal of Indian College of Cardiology 2015; 5(1): 103-6.
9
Chu G, Zhang G, Zhang Z, Liu S, Wen Q, Sun B. Clinical outcome of coronary stenting in patients with variant angina refractory to medical treatment: A consecutive single-center analysis. Med Princ Pract 2013; 22: 583-7.
10
ORIGINAL_ARTICLE
Off-center cardiac rehabilitation focused on extended emotional relationship and common health gains
This article does not have an abstract
https://arya.mui.ac.ir/article_10619_14b6038dc542421e1c565ebade55689b.pdf
2018-01-27
44
45
10.22122/arya.v14i1.1708
Saeid
Komasi
1
Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Ali
Soroush
alisoroush.kums@yahoo.com
2
Lifestyle Modification Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Mozhgan
Saeidi
m_saeidi20@yahoo.com
3
Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
LEAD_AUTHOR
Saeidi M, Komasi S, Heydarpour B, Momeni K, Zakiei A. Those who perceive their disease as a physiological or psychological risk factor experience more anxiety at the beginning of the cardiac rehabilitation program. Res Cardiovasc Med 2016; 5(4): e29291.
1
Heydarpour B, Saeidi M, Ezzati P, Soroush A, Komasi S. Sociodemographic predictors in failure to complete outpatient cardiac rehabilitation. Ann Rehabil Med 2015; 39(6): 863-71.
2
Lavie CJ, Arena R, Franklin BA. Cardiac
3
rehabilitation and healthy life-style interventions: Rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol 2016; 67(1): 13-5.
4
Komasi S, Saeidi M. Hybrid cardiac rehabilitation as an alternative to common hospital-based cardiac rehabilitation in Iran: An appropriate model for the Iranian health system limitations, culture, and patients. Res Cardiovasc Med 2017; 6(2): e13378.
5
Komasi S, Saeidi M, Ezzati P, Amirian J. How can we deliver outpatient cardiac rehabilitation services to all low-risk patients in Iran? Res Cardiovasc Med 2017; 6(2): e13385.
6
Silva AK, Barbosa MP, Bernardo AF, Vanderlei FM, Pacagnelli FL, Vanderlei LC. Cardiac risk stratification in cardiac rehabilitation programs: A review of protocols. Rev Bras Cir Cardiovasc 2014; 29(2): 255-65.
7
Reblin M, Uchino BN. Social and emotional support and its implication for health. Curr Opin Psychiatry 2008; 21(2): 201-5.
8
Woodgate J, Brawley LR, Shields CA. Social support in cardiac rehabilitation exercise maintenance: Associations with self-efficacy and health-related quality of life. J Appl Soc Psychol 2007; 37(5): 1041-59.
9
Ozbay F, Johnson DC, Dimoulas E, Morgan CA, Charney D, Southwick S. Social support and resilience to stress: From neurobiology to clinical practice. Psychiatry (Edgmont) 2007; 4(5): 35-40.
10
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue.
https://arya.mui.ac.ir/article_10611_628a64f39903e0ad85048a0a89ace525.pdf
2018-01-01
10.22122/arya.v14i1.1792
Index
Journal
arya@mui.ac.ir
1
LEAD_AUTHOR